Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Frank Maddux
FDA approves Korsuva as treatment for pruritus in patients on hemodialysis
August 25, 2021 1 min read Save Source/Disclosures ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Kidney Patients Must Not Be Excluded from Accessing Needed Care During the COVID-19 Pandemic
Frank Maddux, MD, FACP, Global Chief Medical Officer Member of the Management Board Fresenius Medical Care - Wednesday, April 22nd, 2020 Print | Email In various locations in the U.S. and in countries around the world, it has recently come to our attention that both private healthcare organizations and governmental entities may be considering policy that would exclude chronic kidney disease patients with end stage kidney disease from accessing intensive care during the COVID-19 pandemic.
FDA approval of on-body sensor may benefit patients with ESKD on home dialysis
BioIntelliSense has received FDA approval to market BioSticker, an on-body sensor that allows for continuous monitoring of vital signs of patients in home settings, including dialysis care. “We believe this device provides an opportunity to transform how we monitor patients on dialysis at home,” Frank Maddux, MD, global chief medical officer for Fresenius Medical Care, told Healio Nephrology.
Fresenius data show 38% of AKI patients recover kidney function
ClinicalPerspective Nephrology News & Issues, March 2019 An analysis of 9,000 patients with diagnosed acute kidney injury treated at Fresenius Medical Care North America outpatient clinics indicates that about one-third of patients will recover kidney function within 90 days of starting in-center hemodialysis and one in six with persistent AKI will recover kidney function by 150 days.
Fresenius invests in remote health monitoring platform from BioIntelliSense
Fresenius Medical Care North America has invested in BioIntelliSense, a company developing a remote, continuous health monitoring data platform. The platform provides predictive analytics, clinical insights and real-time data through medical-grade sensors. Fresenius Medical Care North America (FMCNA) completed the investment to improve monitoring, treatment and outcomes for patients with kidney disease, the company said in a press release.
Fresenius data show one in six patients with AKI regain kidney function
An analysis of 9,000 patients with diagnosed acute kidney injury treated at Fresenius Medical Care North America outpatient clinics indicates that about one-third of patients will recover kidney function within 90 days of starting in-center hemodialysis and one in six with persistent AKI will recover kidney function by 150 days. Overall, 38% of patients recovered kidney function within 150 days of initiating outpatient therapy, the company said in a press release.
Peripheral medical vision can save lives
Five years ago, my life required saving and I didn’t even know it.At that time, I was a doctor of 27 years, only 52 years old, a respected voice in my field, healthy by most accounts, lying on an exam table like many before me watching my heart on a monitor. Unlike millions of Americans who get this evaluation every year, I knew with one glance that the obstructed blood vessel on the monitor would require a serious procedure.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Frank
Contact Frank, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack